Researcher index
Authors in the psilocybin and psilocin literature
Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.
Publication history
Real-World Psilocybin Therapy for Treatment-Resistant Depression: a Retrospective Observational StudyResearch Square · 2025-12-10Meditation, psychedelics, and brain connectivity: A randomized controlled resting-state fMRI study of N,N-dimethyltryptamine and harmine in a meditation retreatUniversität Zürich, ZORA · 2025-09-29Meditation, Psychedelics, and Brain Connectivity: A Randomised Controlled Resting-State fMRI Study of N,N-Dimethyltryptamine and Harmine in a Meditation RetreatmedRxiv · 2025-07-30595. Psilocybin-Assisted Therapy for Relapse Prevention in Alcohol Use Disorder: A RCTBiological Psychiatry · 2025-04-09Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trialUniversität Zürich, ZORA · 2025-04-01The influence of psilocybin on subconscious and conscious emotional learning.iScience · 2024-06-21Comparing Neural Correlates of Consciousness: From Psychedelics to Hypnosis and Meditation.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2024-05-01Author Correction: Psilocybin enhances insightfulness in meditation: a perspective on the global topology of brain imaging during meditation.Scientific reports · 2024-04-23Psilocybin enhances insightfulness in meditation: a perspective on the global topology of brain imaging during meditation.Scientific reports · 2024-03-26TMS-EEG and resting-state EEG applied to altered states of consciousness: oscillations, complexity, and phenomenology.iScience · 2023-05-19Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial.EClinicalMedicine · 2023-02-01Corrigendum to 'Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial'.EClinicalMedicine · 2023-02-01Psychedelics in the treatment of unipolar and bipolar depression.International journal of bipolar disorders · 2022-07-05Psilocybin Induces Time-Dependent Changes in Global Functional Connectivity.Biological psychiatry · 2020-07-15Psilocybin exerts distinct effects on resting state networks associated with serotonin and dopamine in micebioRxiv · 2019-09-01Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination.European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology · 2018-06-01LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation.Frontiers in pharmacology · 2017-01-01Psilocybin-induced decrease in amygdala-putamen coupling during an event-related face discrimination taskEuropean Neuropsychopharmacology · 2016-10-01Effects of serotonin 2A/1A receptor stimulation on social exclusion processing.Proceedings of the National Academy of Sciences of the United States of America · 2016-05-03The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity.NeuroImage. Clinical · 2016-01-01Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.Biological psychiatry · 2015-10-15Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations.Psychopharmacology · 2015-10-01Spatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A/2A receptor agonist psilocybin.Cerebral cortex (New York, N.Y.: 1991) · 2014-12-01P.1.g.005 Serotonergic modulation of emotion processing by the mixed 5-HT1A/2A receptor agonist psilocybin reduces amygdala activation to negative stimuli - a pharmacological fMRI studyEuropean Neuropsychopharmacology · 2014-09-25The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions.Psychopharmacology · 2013-01-01Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors.Biological psychiatry · 2012-12-01Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2012-03-01